Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-10-09Clinical Trial Update: Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer [Phase 3]
Phase 3 trial evaluating palonosetron and dexamethasone with or without dronabinol for prevention of chemotherapy-induced nausea and vomitin…
-
FDA approval · 2020-09-08FDA Approved: FOSAPREPITANT DIMEGLUMINE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved fosaprepitant dimeglumine from Hikma as a generic injectable antiemetic to prevent chemotherapy- and postoperative-induced naus…
-
CLINICAL_TRIALS trial_result · 2020-08-19Clinical Trial Update: Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy [Phase 3]
Phase 3 trial assessing feasibility of olanzapine at reduced dose for highly emetogenic chemotherapy; completed.
-
FDA approval · 2020-08-17FDA Approved: FOSAPREPITANT — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for fosaprepitant (generic) submitted by Mylan Institutional LLC.
-
CLINICAL_TRIALS trial_result · 2020-07-29Clinical Trial Update: Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets [Phase 1, Phase 2]
Phase 1/2 crossover trial comparing ondansetron orally dissolving film strip (ODFS) to Zofran orally disintegrating tablets for postoperativ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-06-12Clinical Trial Update: the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of a 5-HT3 receptor antagonist, dexamethasone, or dispersible tablets of megestrol…
-
FDA label_change · 2020-05-27FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for AKYNZEO (fosnetupitant and palonosetron) submitted by Helsinn Therapeutics (U.S.), Inc., typical…
-
FDA approval · 2020-04-30FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
The FDA approved Cumberland Pharmaceuticals' supplemental application for SANCUSO (granisetron). This action approves an additional regulato…
-
CLINICAL_TRIALS trial_result · 2020-04-15Clinical Trial Update: A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer [Phase 3]
Phase 3 trial comparing IV fosnetupitant/palonosetron to oral netupitant/palonosetron for prevention of chemotherapy-induced nausea and vomi…
-
CLINICAL_TRIALS trial_result · 2020-04-07Clinical Trial Update: Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study [Phase 2]
A Phase 2 feasibility study assessing olanzapine for preventing chemotherapy-induced nausea and vomiting in children has completed with resu…
-
CLINICAL_TRIALS trial_result · 2020-04-03Clinical Trial Update: Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin [Phase 3]
Phase 3 trial investigating a dexamethasone-sparing approach including NEPA for chemotherapy-induced nausea and vomiting due to cisplatin.
-
FDA approval · 2020-04-01FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for palonosetron hydrochloride from Cipla USA Inc.
-
FDA approval · 2020-02-24FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for AKYNZEO (fosnetupitant and palonosetron) from Helsinn Therapeutics (U.S.), Inc. to support i…
-
FDA approval · 2020-02-10FDA Approved: FOSAPREPITANT — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for fosaprepitant submitted by Novadoz Pharmaceuticals LLC to expand its labeling.
-
FDA approval · 2020-02-07FDA Approved: DRONABINOL — Original Application (Camber Pharmaceuticals Inc)
FDA approves Camber Pharmaceuticals' original abbreviated new drug application for dronabinol (generic). The product is indicated for chemot…
-
FDA approval · 2019-11-14FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (aprepitant) from Merck Sharp & Dohme LLC to expand its approved use as an antiemetic for …
-
FDA approval · 2019-11-14FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) filed by Merck Sharp & Dohme LLC.
-
FDA approval · 2019-11-14FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) filed by Merck Sharp & Dohme LLC.
-
FDA approval · 2019-10-30FDA Approved: METOCLOPRAMIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for metoclopramide hydrochloride from Fresenius Kabi USA, LLC.
-
FDA approval · 2019-10-29FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for palonosetron hydrochloride from Sandoz Inc, authorizing changes under the ANDA pathway.
-
FDA approval · 2019-10-21FDA Approved: CINVANTI — Supplemental Application (Heron Therapeutics, Inc.)
The FDA approved a supplemental application for CINVANTI (aprepitant) submitted by Heron Therapeutics, Inc.
-
FDA approval · 2019-09-25FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (aprepitant) filed by Merck Sharp & Dohme LLC, resulting in updated labeling for the produ…
-
FDA approval · 2019-09-25FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) by Merck Sharp & Dohme LLC.
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (Actavis Pharma, Inc.)
The FDA approved fosaprepitant as an intravenous antiemetic based on the original NDA submitted by Actavis Pharma, Inc. for prevention of ch…
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (Mylan Institutional LLC)
FDA approves a generic version of fosaprepitant from Mylan Institutional LLC via an Original Application (ANDA) to prevent chemotherapy-indu…